Expression profile and prognostic value of linc00346 and E2F2 in liver cancer

ZHU Yu; LIU Hao-han; DING Lei; LIANG Ya-li; WEN Yu-feng

doi:10.16462/j.cnki.zhjbkz.2020.02.020

Volume 24 Issue 2

Feb. 2020

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2020 > 24(2): 228-232

ZHU Yu, LIU Hao-han, DING Lei, LIANG Ya-li, WEN Yu-feng. Expression profile and prognostic value of linc00346 and E2F2 in liver cancer[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(2): 228-232. doi: 10.16462/j.cnki.zhjbkz.2020.02.020

Citation:

ZHU Yu, LIU Hao-han, DING Lei, LIANG Ya-li, WEN Yu-feng. Expression profile and prognostic value of linc00346 and E2F2 in liver cancer[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2020, 24(2): 228-232. doi: 10.16462/j.cnki.zhjbkz.2020.02.020

Citation:

PDF( 1076 KB)

Expression profile and prognostic value of linc00346 and E2F2 in liver cancer

doi: 10.16462/j.cnki.zhjbkz.2020.02.020

ZHU Yu^{1, 2},
LIU Hao-han²,
DING Lei²,
LIANG Ya-li²,
WEN Yu-feng^{2
,
,}

1.
Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution, Wannan Medical College, Wuhu 241002, China
2.
School of Public Health, Wannan Medical College, Wuhu 241002, China

Funds: The Open Project of Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution(Wannan Medical College)(RNA201908); Excellent Teachers Program in Higher Education Institutions of Anhui(gxfx2017068)

More Information

Corresponding author: WEN Yu-feng, E-mail:wyf@wnmc.edu.cn
Received Date: 2019-08-27
Publish Date: 2020-02-10

Abstract

Abstract

Objective To investigate the expression pattern of linc00346 and E2 F2, and its prognostic value on liver cancer. Methods Gene expression profile data of patients with liver cancer was downloaded from the cancer genome atlas(TCGA) database. Paired t test was used to evaluate the differential expression of linc00346 and E2 F2 from tissues and matched adjacent normal tissues. Co-expression analysis of linc00346 and E2 F2 was performed using Pearson correlation. Log-Rank test and Cox proportional hazards regression were used to estimate prognostic value of linc00346 and E2 F2. Results linc00346 and E2 F2 expression were upregulated in liver cancer tissue specimens(all P < 0.05), and fold change was 2.24 and 3.72, respectively. Pearson coefficient was 0.20(P < 0.001). Patient with linc00346 and E2 F2 high expression had a 1.77(95 %CI: 1.23-2.55) and 2.19(95 % CI: 1.51-3.17) times higher hazard of death than those with linc00346 and E2 F2 low expression, respectively. However, only E2 F2 was significantly associated with the prognosis of liver cancer in multiple Cox regression. Conclusions linc00346 and E2 F2 expressions are upregulated in liver cancer tissues, and patients with linc00346 and E2 F2 high expressions has poor prognosis. It is of great significance to discover linc00346 and E2 F2 as a novel therapeutic target for liver cancer.
- linc00346,
- E2F2,
- liver cancer,
- Prognostic

FullText(HTML)

References(25)

References

[1]	Gao J, Yin X, Yu X, et al. Long noncoding RNA linc00488 functions as a ceRNA to regulate hepatocellular carcinoma cell growth and angiogenesis through miR-330-5[J]. Dig Liver Dis, 2019, 51(7): 1050-1059. DOI: 10.1016/j.dld.2019.03.012.
[2]	Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. A Cancer J Clin, 2016, 66(2): 115-132. DOI: 10.3322/caac.21338.
[3]	Suh JK, Lee J, Lee JH, et al. Risk factors for developing liver cancer in people with and without liver disease[J]. PLoS One. 2018, 29, 13(10): e0206374. DOI: 10.1371/journal.pone.0206374.
[4]	McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability[J]. Clin Liver Dis, 2015, 19(2): 223-38. DOI: 10.1016/j.cld.2015.01.001.
[5]	Perz JF, Armstrong GL, Farrington LA, et al.. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J]. J Hepatol, 2006, 45(4): 529-38. doi: 10.1016/j.jhep.2006.05.013
[6]	Cui Y, Jia J. Update on epidemiology of hepatitis B and C in China[J]. J Gastroenterol Hepatol, 2013, Suppl 1: 7-10. DOI: 10.1111/jgh.12220.
[7]	Marengo A, Rosso C, Bugianesi E. Liver cancer: connections with obesity, fatty liver, and cirrhosis[J]. Annu Rev Med, 2016, 67: 103-117. DOI: 10.1146/annurev-med-090514-013832.
[8]	Forner A, Reig M, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2018, 31, 391(10127): 1301-14. DOI: 10.1016/S0140-6736(18)30010-2.
[9]	Sia D, Villanueva A, Friedman SL, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152(4): 745-761. DOI: 10.1053/j.gastro.2016.11.048.
[10]	Xu TP, Ma P, Wang WY, et al. KLF5 and MYC modulated linc00346 contributes to gastric cancer progression through acting as a competing endogeous RNA and indicates poor outcome[J]. Cell Death Differ, 2019, 26(11): 2179-2193. DOI: 10.1038/s41418-018-0236-y.
[11]	Shi W, Zhang C, Ning Z, et al. Long non-coding RNA linc00346 promotes pancreatic cancer growth and gemcitabine resistance by sponging miR-188-3p to derepress BRD4 expression[J]. J Exp Clin Cancer Res, 2019, 38(1): 60. DOI: 10.1186/s13046-019-1055-9.
[12]	Hsu SD, Tseng YT, Shrestha S, et al. miRTarBase update 2014: an information resource for experimentally validated miRNA-target interactions[J]. Nucleic Acids Res, 2014, 42(Database issue): D78-D85. DOI: 10.1093/nar/gkt1266.
[13]	Jeggari A, Marks DS, Larsson E. miRcode: a map of putative microRNA target sites in the long non-coding transcriptome[J]. Bioinformatics, 2012, 28(15): 2062-2063. DOI: 10.1093/bioinformatics/bts344.
[14]	Hothorn T, Lausenon B. On maximally selected rank statistics[J]. R News, 2002, 2(1): 3-5.
[15]	Peng Z, Liu C, Wu M. New insights into long noncoding RNAs and their roles in glioma[J]. Mol Cancer, 2018, 17(1): 61. DOI: 10.1186/s12943-018-0812-2.
[16]	Chen X, Fan S, Song E. Non-coding RNAs: new players in cancers[J]. Adv Exp Med Biol, 2016, 927: 1-47. DOI: 10.1007/978-981-10-1498-7_1.
[17]	Liu Z, Wang Y, Wang L, et al. Long non-coding RNA AGAP2-AS1, functioning as a competitive endogenous RNA, upregulates ANXA11 expression by sponging miR-16-5p and promotes proliferation and metastasis in hepatocellular carcinoma[J]. J Exp Clin Cancer Res, 2019, 38(1): 194. DOI: 10.1186/s13046-019-1188-x.
[18]	Peng Y, Leng W, Duan S, et al. Long noncoding RNA BLACAT1 is overexpressed in hepatocellular carcinoma and its downregulation suppressed cancer cell development through endogenously competing against hsa-miR-485-5p[J]. Biomed Pharmacother, 2019, 116: 109027. DOI: 10.1016/j.biopha.2019.109027.
[19]	Wu DM, Zheng ZH, Zhang YB, et al. Down-regulated lncRNA DLX6-AS1 inhibits tumorigenesis through STAT3 signaling pathway by suppressing CADM1 promoter methylation in liver cancer stem cells[J]. J Exp Clin Cancer Res, 2019, 38(1): 237. DOI: 10.1186/s13046-019-1239-3.
[20]	Wang F, Chen JG, Wang LL, et al. Up-regulation of LINC00346 inhibits proliferation of non-small cell lung cancer cells through mediating JAK-STAT3 signaling pathway[J]. Eur Rev Med Pharmacol Sci, 2017, 21(22): 5135-5142. DOI: 10.26355/eurrev_201711_13830.
[21]	Ye T, Ding W, Wang N, et al. Long noncoding RNA linc00346 promotes the malignant phenotypes of bladder cancer[J]. Biochem Biophys Res Commun, 2017, 491(1): 79-84. DOI: 10.1016/j.bbrc.2017.07.045.
[22]	Castillo DS, Campalans A, Belluscio LM, et al. E2F1 and E2F2 induction in response to DNA damage preserves genomic stability in neuronal cells[J]. Cell Cycle, 2015, 14(8): 1300-1314. DOI: 10.4161/15384101.2014.985031.
[23]	Yuwanita I, Barnes D, Monterey MD, et al. Increased metastasis with loss of E2F2 in Myc-driven tumors[J]. Oncotarget, 2015, 6(35): 38210-38224. DOI: 10.18632/oncotarget.5690.
[24]	Sun CC, Li SJ, Hu W, et al. Comprehensive analysis of the expression and prognosis for E2Fs in human breast cancer[J]. Mol Ther, 2019, 27(6): 1153-1165. DOI: 10.1016/j.ymthe.2019.03.019.
[25]	Xie L, Li T, Yang LH. E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival[J]. Eur Rev Med Pharmacol Sci, 2017, 21(9): 2150-2156. http://www.ncbi.nlm.nih.gov/pubmed/28537669